Toronto, Ontario – June 26, 2017
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that the U.S. Patent and Trademark Office (“USPTO”) has issued a second patent on its lead anti-cancer compound technology licensed by Theralase from Dr. Sherri McFarland.
The USPTO granted U.S. Patent Number 9,676,806 B2 entitled, “Metal-Based Thiophene Photodynamic Compounds and Their Use”, which issued on June 13, 2017, as a continuation of U.S. Patent No. 9,345,769.